MALDI-MSI and label-free LC-ESI-MS/MS shotgun proteomics to investigate protein induction in a murine fibrosarcoma model following treatment with a vascular disrupting agent.

@article{Cole2014MALDIMSIAL,
  title={MALDI-MSI and label-free LC-ESI-MS/MS shotgun proteomics to investigate protein induction in a murine fibrosarcoma model following treatment with a vascular disrupting agent.},
  author={Laura M. Cole and Joanne E Bluff and Vikki A Carolan and Martyn N Paley and Gillian M. Tozer and Malcolm R Clench},
  journal={Proteomics},
  year={2014},
  volume={14 7-8},
  pages={890-903}
}
Tumour vasculature is notoriously sinusoidal and leaky, and is hence susceptible to vascular disruption. Microtubule destabilising drugs such as the combretastatins form the largest group of tumour vascular disrupting agents and cause selective shutdown of tumour blood flow within minutes to hours, leading to secondary tumour cell death. Targeting the tumour vasculature is a proven anticancer strategy but early treatment response biomarkers are required for personalising treatment planning… CONTINUE READING